Chiron has received a license for its new meningococcal B vaccine for New Zealand Chiron Corporation today announced that it has received a license for its new meningococcal B vaccine for New Zealand, MeNZB. Meningococcal disease results from infection caused by the bacterium Neisseria meningitidis, known as meningococcus. Meningococcal disease usually affects the membranes around the brain and spinal cord or the bloodstream, causing septicemia or meningitis, respectively. Meningococcal disease can result in brain harm, blindness, deafness, limb amputations and death. Infection could be fatal if diagnosed early actually, making prevention important.2. About AstraZeneca AstraZeneca is a global, innovation-powered biopharmaceutical business that focuses on the discovery, commercialisation and development of prescription medications, primarily for the treatment of cardiovascular, metabolic, respiratory, swelling, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by an incredible number of patients worldwide.. Beating cancer – – how exactly to take charge of your cancers get rid of and outlive the lies of the cancers industry Here’s a good example of how backwards healthcare is really in this country: that it is front-page news a cancer middle is serving anti-tumor foods in its cafeteria.